TABLE 2.
Performance of Morphologic Assessment and p57 Immunostaining for Predicting a Genotyping-Confirmed Diagnosis of CHM
| Diagnosis of CHM (CHM vs. PHM+NM) | Sensitivity (%) | Specificity (%) | Positive Predictive Value (%) | Negative Predictive Value (%) |
|---|---|---|---|---|
| Pathologist 1 | ||||
| Round 1 | 63 | 94 | 85 | 83 |
| Round 2 | 63 | 94 | 85 | 83 |
| Round 3 (p57) | 93 | 96 | 93 | 96 |
| Pathologist 2 | ||||
| Round 1 | 96 | 92 | 87 | 98 |
| Round 2 | 100 | 91 | 84 | 100 |
| Round 3 (p57) | 96 | 96 | 93 | 98 |
| Pathologist 3 | ||||
| Round 1 | 59 | 96 | 89 | 82 |
| Round 2 | 78 | 96 | 91 | 89 |
| Round 3 (p57) | 93 | 98 | 96 | 96 |
| Consensus diagnosis | ||||
| Round 1 | 70 | 98 | 95 | 87 |
| Round 2 | 81 | 94 | 88 | 91 |
| Round 3 (p57) | 96 | 96 | 93 | 98 |
CHM indicates complete hydatidiform mole (either classic or early type); NM, non-molar specimen; PHM, partial hydatidiform mole.